Verified email-pattern data for Biophenyx is currently limited. You can still use the company insights and contact sections below.
BioPhenyx minimize trial and error in drug discovery and use, offering better outcomes for pharma and patients, from the power of CRISPR-Select.
CRISPR-Select can conclusively determine the potential role of any gene and gene-variants in disease development and - if relevant - how to most effectively target these.
This include variants of essential genes, not possible before.
This principle can profoundly impact how medicines, and other related biotechnology innovations, are developed and used.
For Pharma R&D we may significantly positively impact outcomes of development programs, by early selection of disease relevant variants and deselection of non-relevant variants, and e.g. prove or disprove hypotheses generated or suggested by other technologies such as High Throughput Screening (HTS), Genome Wide Association Studies (GWAS), and/or Artificial Intelligence (AI).
Technically we use our proprietary CRISPR-Select technology to tailor the "competition" for 1) "survival" or 2) selection of a specific trait, aka "phenotype", between two or more simultaneously CRISPR knocked-in gene-variants in a cell population.
We grow the cell population for a few weeks under 1) selection pressure or 2) select for a relevant marker and then quantify the evolved difference between the gene-variants in the cell population.
For quantification we use Polymerase Chain Reaction (PCR) and deep Next Generation Sequencing (NGS) of the pooled or "over-layered" variants.
If there is no difference in quantity, the two or more variants will have the same (i.e. no) role in disease development.
A large difference imply a large role in disease development.
So far all known benign and pathogenic variants with known outcomes from ClinVar, measured with CRISPR-Select, correlates 100%.
Consequently, CRISPR-Select is used by local hospitals, and work is ongoing to scale up the assay process.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Nordre Fasanvej 215, Frederiksberg,capital Region Of Denmark 2000,denmark
- Industry
- Biotechnology Research
- Website
- https://biophenyx.com/
- Keywords
- to help you:.
- HQ
- Frederiksberg, Capital Region of Denmark
Biophenyx Questions
BioPhenyx's website is https://biophenyx.com/
BioPhenyx's LinkedIn profile is https://dk.linkedin.com/company/biophenyx-aps
BioPhenyx has
1 employees.
View email and phone details for 1
employees at BioPhenyx.
BioPhenyx's industry is
Biotechnology Research
BioPhenyx's top competitors are
Lead Biologics,
Transient Pharma Ab,
Adcendo,
Mycural Therapeutics,
Aax Biotech Ab,
Galantus,
Mole - Molecular Engineering Lab @ Politecnico Di Torino,
Alcolase,
Sortina Pharma,
Rpmahealthcare.
BioPhenyx's categories are Biotechnology Research
BioPhenyx's founding year is 2022
Explore related pages
Related company profiles:
Top BioPhenyx Employees
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.